Title: A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients
Authors: Van Cutsem, Eric ×
Verslype, Chris
Beale, P
Clarke, S
Bugat, R
Rakhit, A
Fettner, S. H
Brennscheidt, U
Feyereislova, A
Feyereislova, A
Delord, J. -P #
Issue Date: Feb-2008
Publisher: Oxford univ press
Series Title: Annals of oncology vol:19 issue:2 pages:332-339
Abstract: Background: Dysregulation of the epidermal growth factor receptor (HER1/EGFR) has been reported in colorectal cancer (CRC). Erlotinib is a potent inhibitor of HER1/EGFR-mediated signaling. This trial of patients with metastatic CRC (MCRC) examined the safety, maximum tolerated dose (MTD) and pharmacokinetics (PK) of erlotinib in combination with capecitabine and oxaliplatin (XELOX), a regimen with established efficacy.
ISSN: 0923-7534
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Hepatology
Translational Research in GastroIntestinal Disorders
Clinical Digestive Oncology (+)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science